Neuropeptide Y Y1 receptor Structures Offer New Opportunities for Anti-obesity Drug Discovery

News provided by

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

19 Apr, 2018, 08:00 GMT

- Structures of human neuropeptide Y receptor Y1R reveal drug recognition mechanisms

SHANGHAI, April 19, 2018 /PRNewswire/ -- Obesity is a major public health concern. Each year, millions of people die from obesity related diseases, such as diabetes and cardiovascular disease. Neuropeptide Y (NPY) is the most powerful stimulant of food intake and this effect is primarily mediated by the Y1 receptor (Y1R). Thus, Y1R serves as an important drug target for many human diseases, such as obesity, type 2 diabetes and metabolic syndrome. However, the clinical usage of Y1R ligands has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability.

The new Nature study reports the structure of the human neuropeptide Y receptor Y1R, which is involved in regulation of food intake and energy homeostasis, and serves as an important drug target for obesity and type 2 diabetes. (Image courtesy of Dr. Beili Wu’s group from SIMM.)
The new Nature study reports the structure of the human neuropeptide Y receptor Y1R, which is involved in regulation of food intake and energy homeostasis, and serves as an important drug target for obesity and type 2 diabetes. (Image courtesy of Dr. Beili Wu’s group from SIMM.)

Recently, scientists from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), in collaboration with several groups based in Germany, United States, China and Sweden, determined the high-resolution atomic structures of human Y1R bound to two structurally diverse antagonists UR-MK299 and BMS-193885, providing a detailed molecular map of Y1R and invaluable insights into understanding the pharmacology of NPY receptor. The study was recently published in Nature.

The Y1R structures reveal, for the first time, the molecular details of an NPY receptor binding to its ligand at atomic level, and provide an accurate template for drug design targeting Y1R. The structures combined with mutagenesis, ligand binding and signaling studies elucidate the binding modes of Y1R to various antagonists and the molecular mechanisms of ligand selectivity in different NPY receptors. These findings offer new opportunities for anti-obesity drug discovery.

Based on the Y1R structure, the researchers performed extensive studies including complementary mutagenesis, cell signaling, nuclear magnetic resonance, molecular docking and photo-crosslinking. The results provide insights into the binding behavior of the endogenous agonist NPY to Y1R, and for the first time identified the binding site of NPY N terminus, which is critical for receptor selectivity, in Y1R. These insights into Y1R expand our understanding of NPY receptor signal transduction and lay a foundation for carrying out structure-based drug discovery that targets this physiologically important receptor.

Photo - https://mma.prnewswire.com/media/679221/Neuropeptide_Y_receptor_Y1R.jpg